PHAT
Price
$12.83
Change
-$0.98 (-7.10%)
Updated
Feb 4, 03:10 PM (EDT)
Capitalization
1.08B
27 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.85
Change
-$0.24 (-5.85%)
Updated
Feb 4, 03:16 PM (EDT)
Capitalization
2.13B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PHAT vs RXRX

Header iconPHAT vs RXRX Comparison
Open Charts PHAT vs RXRXBanner chart's image
Phathom Pharmaceuticals
Price$12.83
Change-$0.98 (-7.10%)
Volume$490
Capitalization1.08B
Recursion Pharmaceuticals
Price$3.85
Change-$0.24 (-5.85%)
Volume$38.2K
Capitalization2.13B
PHAT vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
PHAT vs. RXRX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (PHAT: $13.81 vs. RXRX: $4.10)
Brand notoriety: PHAT and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 88% vs. RXRX: 108%
Market capitalization -- PHAT: $1.08B vs. RXRX: $2.13B
PHAT [@Biotechnology] is valued at $1.08B. RXRX’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both PHAT and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 2 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • PHAT’s TA Score: 2 bullish, 7 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than PHAT.

Price Growth

PHAT (@Biotechnology) experienced а -2.95% price change this week, while RXRX (@Biotechnology) price change was -10.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

PHAT is expected to report earnings on Mar 03, 2026.

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.13B) has a higher market cap than PHAT($1.08B). RXRX YTD gains are higher at: 0.244 vs. PHAT (-16.757). PHAT has higher annual earnings (EBITDA): -203.56M vs. RXRX (-636.09M). RXRX has more cash in the bank: 660M vs. PHAT (135M). RXRX has less debt than PHAT: RXRX (82.4M) vs PHAT (210M). PHAT has higher revenues than RXRX: PHAT (147M) vs RXRX (43.4M).
PHATRXRXPHAT / RXRX
Capitalization1.08B2.13B50%
EBITDA-203.56M-636.09M32%
Gain YTD-16.7570.244-6,854%
P/E RatioN/AN/A-
Revenue147M43.4M339%
Total Cash135M660M20%
Total Debt210M82.4M255%
FUNDAMENTALS RATINGS
PHAT: Fundamental Ratings
PHAT
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHATRXRX
RSI
ODDS (%)
Bearish Trend 6 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UUOAX22.750.09
+0.40%
GMO U.S. Opportunistic Value Vi
GLNLX24.470.08
+0.33%
MFS Global New Discovery R3
CVSOX15.81-0.01
-0.06%
Calamos Market Neutral Income R6
TWGAX14.17-0.13
-0.91%
American Century International Gr A
STDFX39.69-0.77
-1.90%
Allspring Large Cap Growth Admin

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with QCLS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then QCLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
N/A
QCLS - PHAT
39%
Loosely correlated
-1.76%
URGN - PHAT
36%
Loosely correlated
+1.52%
RGNX - PHAT
36%
Loosely correlated
+0.74%
ATRA - PHAT
36%
Loosely correlated
N/A
ALGS - PHAT
33%
Loosely correlated
-5.41%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-1.91%
CRSP - RXRX
69%
Closely correlated
+1.34%
ABSI - RXRX
63%
Loosely correlated
+2.32%
BEAM - RXRX
61%
Loosely correlated
-0.11%
ABCL - RXRX
58%
Loosely correlated
+0.57%
PRME - RXRX
55%
Loosely correlated
+0.26%
More